News & Analysis on Clinical Trial Services & Contract Research And Development
A clear timeline and stepwise approach to a US solution for tracking and tracing pharmaceuticals through the supply chain to root out counterfeits is necessary, stakeholders agreed.
In a quarter that has seen the company divest its contract packaging and Canadian drug distribution arms, AmerisourceBergen’s Q2 results have been deemed “less than special” by analysts.
The US Department of Justice’s Attorney’s Office in Boston has sent subpoenaed documents related to AstraZeneca's UK manufacturing practices, which the company said it is complying with.
Icon’s first quarter FY2013 revenue increased 26% year on year, besting analysts’ expectations and resulting in a nearly 7% increase in the company’s stock price.
LIVE FROM INTERPHEX
Purification bottlenecks, integrating single-use technologies and low cost companies are just some of the issues affecting the biotech industry today, according to experts at this year’s Interphex.